Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis

Experimental Hematology

Volumn 36, Issue 1, 2008, Pages 1-8

  Ogawa, Hiroyasu ^a,b   Ikegame, Kazuhiro ^b   Kaida, Katsuji ^b   Yoshihara, Satoshi ^b   Fujioka, Tatsuya ^b   Taniguchi, Yuki ^b   Tamaki, Hiroya ^b   Inoue, Takayuki ^b   Hasei, Hitomi ^a   Iiboshi, Yasuhiko ^b   Tazuke, Yuko ^b   Kawakami, Manabu ^a   Kim, Eui Ho ^a   Soma, Toshihiro ^a   Inoue, Takehiro ^a   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GANCICLOVIR; HLA A2 ANTIGEN; HLA A3 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VANCOMYCIN;

ADULT; ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FATALITY; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER TOXICITY; MALE; MYCOSIS; MYELOABLATIVE CONDITIONING; NEUTROPHIL; ORGAN DONOR; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; SURVIVAL; THROMBOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS INFECTION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVING DONORS; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYELOABLATIVE AGONISTS; POSTOPERATIVE COMPLICATIONS; TACROLIMUS; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 37249030518     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.08.013     Document Type: Article

References (27)

1. Armitage J.O. Medical progress. Bone marrow transplantation. N Engl J Med 330 (1994) 827-838
2. Henslee-Downey P.J., Abhyankar S.H., Parrish R.S., et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89 (1997) 3864-3872
3. Aversa F., Tabilio F., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339 (1998) 1186-1193
4. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
5. Tabilio A., Falzetti F., Zei T., et al. Graft engineering for allogeneic haploidentical stem cell transplantation. Blood Cells Mol Dis 33 (2004) 274-280
6. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313 (1985) 765-771
7. Anasetti C., and Hansen J.A. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 15 (1994) 221-230
8. Ogawa H., Soma T., Hosen N., et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation 74 (2002) 236-243
9. Ogawa H., Ikegame K., Kawakami M., Taniguchi Y., Oka Y., and Kawase I. Allogeneic bone marrow transplantation with non-T-cell-depleted marrow from two HLA-antigen-mismatched related donors. Haematologica 89 (2004) 373-375
10. Siegert W., Josimovic-Alasevic O., Schwerdtfeger R., et al. Soluble interleukin 2 receptors after bone marrow transplantation. Bone Marrow Transplant 6 (1990) 97-101
11. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host diseases in human recipients of marrow from HLA matched sibling donors. Transplantation 18 (1974) 295-304
12. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
13. Eizuru Y., Minematsu T., Minamishima Y., et al. Rapid diagnosis of cytomegalovirus infections by direct immunoperoxidase staining with human monoclonal antibody against an immediate-early antigen. Microbiol Immunol 35 (1991) 1015-1022
14. Zeigler Z.R., Shadduck R.K., Nemunaitis J., Andrews D.F., and Rosenfeld C.S. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 15 (1995) 247-253
15. Nishida T., Hamaguchi M., Hirabayashi N., et al. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 33 (2004) 1143-1150
16. Ogawa H., Ikegame K., Yoshihara S., et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 12 (2006) 1073-1084
17. Taniguchi Y., Ikegame K., Yoshihara S., Sugiyama H., Kawase I., and Ogawa H. Treatment of severe life-threatening graft-versus-host disease by autologous peripheral blood stem cell transplantation using a nonmyeloablative preconditioning regimen. Haematologica 88 (2003) ELT06
18. Yoshihara S., Kato R., Inoue T., et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone HLA-haploidentical nonmyeloablative stem cell transplantation. Transplantation 77 (2004) 835-838
19. Ferrara J.L., Levy R., and Chao N.J. Pathophysiology mechanism of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5 (1999) 347-356
20. Holler E., Kolb H.J., Moller A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75 (1990) 1011-1016
21. Scheinman R.I., Cogswell P.C., Lofquist A.K., and Baldwin Jr. A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
22. Bacigalupo A., Oneto R., Lamparelli T., et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 28 (2001) 1093-1096
23. Storb R., Pepe M., Anasetti C., et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?. Blood 76 (1990) 1037-1045
24. Chao N.J., Schmidt G.M., Niland J.C., et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329 (1993) 1225-1230
25. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107 (2006) 3065-3073
26. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
27. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003) 814-819